Abramson Discusses Liso-Cel as a Transformative Therapy in LBCL
Jeremy Abramson, MD, discusses what the findings from the phase 3 TRANSFORM study of lisocabtagene maraleucel mean for patients with relapsed large B-cell lymphoma.
Liso-Cel Shows Clinical Benefit in Relapsed/Refractory LBCL
Jeremy Abramson, MD, discusses findings from the TRANSFORM study of lisocabtagene maraleucel vs standard of care treatment in patients with relapsed or refractory large B-cell lymphoma.
The Rationale for the Phase I TRANSCEND NHL 001 Trial